PT2101740E - Nova composição farmacêutica não susceptível de abuso que compreende opióides - Google Patents

Nova composição farmacêutica não susceptível de abuso que compreende opióides

Info

Publication number
PT2101740E
PT2101740E PT78247848T PT07824784T PT2101740E PT 2101740 E PT2101740 E PT 2101740E PT 78247848 T PT78247848 T PT 78247848T PT 07824784 T PT07824784 T PT 07824784T PT 2101740 E PT2101740 E PT 2101740E
Authority
PT
Portugal
Prior art keywords
opioids
pharmaceutical composition
new non
opioid
abusable
Prior art date
Application number
PT78247848T
Other languages
English (en)
Portuguese (pt)
Inventor
Anders Pettersson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37781988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2101740(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of PT2101740E publication Critical patent/PT2101740E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT78247848T 2006-12-04 2007-12-03 Nova composição farmacêutica não susceptível de abuso que compreende opióides PT2101740E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87249606P 2006-12-04 2006-12-04

Publications (1)

Publication Number Publication Date
PT2101740E true PT2101740E (pt) 2013-12-23

Family

ID=37781988

Family Applications (1)

Application Number Title Priority Date Filing Date
PT78247848T PT2101740E (pt) 2006-12-04 2007-12-03 Nova composição farmacêutica não susceptível de abuso que compreende opióides

Country Status (9)

Country Link
US (5) US8470361B2 (enExample)
EP (1) EP2101740B1 (enExample)
JP (2) JP5484062B2 (enExample)
DK (1) DK2101740T3 (enExample)
ES (1) ES2439581T3 (enExample)
PL (1) PL2101740T3 (enExample)
PT (1) PT2101740E (enExample)
SI (1) SI2101740T1 (enExample)
WO (1) WO2008068471A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
ES2439581T3 (es) 2006-12-04 2014-01-23 Orexo Ab Nueva composición farmacéutica no susceptible de abuso que comprende opioides
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2010008863A1 (en) * 2008-06-23 2010-01-21 Biodelivery Sciences International, Inc. Multidirectional mucosal delivery devices and methods of use
WO2010066034A1 (en) 2008-12-12 2010-06-17 Paladin Labs Inc. Methadone formulation
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
DK2493457T3 (en) 2009-10-30 2017-10-02 Ix Biopharma Ltd QUICK-SOLVING SOLID DOSAGE FORM
US12186426B2 (en) 2009-10-30 2025-01-07 Ix Biopharma Ltd. Solid dosage form
JP6210988B2 (ja) 2011-09-19 2017-10-11 オレクソ・アクチエボラゲット オピオイド依存を治療するための新規乱用耐性医薬組成物
WO2013164617A1 (en) * 2012-05-02 2013-11-07 Orexo Ab New sufentanil composition for the treatment of acute pain
EP3150199B1 (en) 2012-05-02 2018-08-08 Orexo AB New alfentanil composition for the treatment of acute pain
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
US9675587B2 (en) 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US11931227B2 (en) 2013-03-15 2024-03-19 Cook Medical Technologies Llc Bimodal treatment methods and compositions for gastrointestinal lesions with active bleeding
CN103304570A (zh) * 2013-07-12 2013-09-18 四川省惠达药业有限公司 一种盐酸纳洛酮化合物、其制备方法及其药物组合物
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
KR20160108828A (ko) 2013-11-11 2016-09-20 임팩스 라보라토리즈, 인코포레이티드 신속하게 붕괴되는 제형 및 사용 방법
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
WO2016007245A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
RS63319B1 (sr) 2015-09-02 2022-07-29 Trevena Inc Jedinjenja koja modulišu delta-opioidni receptor, koja sadrže 6-člani aza-heterociklik, postupci njihove upotrebe i spravljanja
EP3210596A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical composition
EP3210630A1 (en) * 2016-02-29 2017-08-30 G.L. Pharma GmbH Abuse-deterrent pharmaceutical compositions
US11135217B2 (en) 2016-12-26 2021-10-05 Shionogi & Co., Ltd. Manufacturing process of formulation having improved content uniformity
AU2018221148B2 (en) 2017-02-17 2022-05-05 Trevena, Inc. 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN110446495B (zh) 2017-02-17 2023-09-05 特维娜有限公司 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法
EP3727384A4 (en) 2017-12-20 2021-11-03 Purdue Pharma L.P. ABUSE-DISSUASIVE MORPHINE SULPHATE FORMES
CA3166250A1 (en) 2020-02-05 2021-08-12 Gregory G. Plucinski Drug products for intranasal administration and uses thereof
US20250144015A1 (en) 2023-11-06 2025-05-08 Extrovis Ag Pharmaceutical Compositions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5138412A (en) 1974-09-24 1976-03-31 Nippon Kayaku Kk Kokoseizai no seiho
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
FR2562313B1 (fr) 1984-04-03 1989-04-07 Cogema Procede de decontamination en uranium et en radium de solutions uraniferes acides par addition d'un sel d'aluminium
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
SE9803239D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7842307B2 (en) 2001-08-06 2010-11-30 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US7332182B2 (en) 2001-08-06 2008-02-19 Purdue Pharma L.P. Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US7144587B2 (en) * 2001-08-06 2006-12-05 Euro-Celtique S.A. Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030191147A1 (en) 2002-04-09 2003-10-09 Barry Sherman Opioid antagonist compositions and dosage forms
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
NZ541167A (en) 2003-01-31 2008-07-31 Orexo Ab A rapid-acting pharmaceutical composition comprising e.g. fentanyl and particles insoluble in water
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
WO2006103418A1 (en) 2005-03-28 2006-10-05 Orexo Ab New pharmaceutical compositions useful in the treatment of pain
ES2439581T3 (es) * 2006-12-04 2014-01-23 Orexo Ab Nueva composición farmacéutica no susceptible de abuso que comprende opioides

Also Published As

Publication number Publication date
US8470361B2 (en) 2013-06-25
JP2010511683A (ja) 2010-04-15
US20130195981A1 (en) 2013-08-01
SI2101740T1 (sl) 2014-03-31
US20160151351A1 (en) 2016-06-02
US20100129443A1 (en) 2010-05-27
US20130195982A1 (en) 2013-08-01
ES2439581T3 (es) 2014-01-23
JP5484062B2 (ja) 2014-05-07
EP2101740B1 (en) 2013-11-06
PL2101740T3 (pl) 2014-04-30
US8658198B2 (en) 2014-02-25
DK2101740T3 (da) 2013-11-18
EP2101740A1 (en) 2009-09-23
US20140335190A1 (en) 2014-11-13
WO2008068471A1 (en) 2008-06-12
US8980305B2 (en) 2015-03-17
JP2013249312A (ja) 2013-12-12

Similar Documents

Publication Publication Date Title
PT2101740E (pt) Nova composição farmacêutica não susceptível de abuso que compreende opióides
MY153243A (en) Compound for inhibiting mitotic progression
EA201400246A1 (ru) Новая, не допускающая злоупотребления фармацевтическая композиция для лечения опиоидной зависимости
MX361542B (es) Compuestos de morfinan.
MX370608B (es) Compuestos de morfinano.
WO2008021851A3 (en) Novel compounds as antagonists or inverse agonists for opioid receptors
WO2009059048A3 (en) (+)-opioids and methods of use
IL194651A0 (en) Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse
IL194642A0 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
MY160456A (en) Benzodiazepine bromodomain inhibitor
IL195360A (en) Prodrug of phenolic opioids, a method of preparing them, a drug that includes them and their use
IL210756A0 (en) Carbostyril compound, process for their preparation and pharmaceutical compositions containing them
ZA200701167B (en) Compositions for delivering highly water soluble drugs
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
SI1951232T1 (sl) Postopki za zmanjšanje z alkoholom izzvanega prehitrega sproščanja odmerka (dose dumping) iz opioidnih oralnih dozirnih oblik s podaljšanim sproščanjem
IL194734A0 (en) Pharmaceutical compositions containing opioid antagonists
EP2214770A4 (en) METHODS, KITS AND COMPOSITIONS FOR ADMINISTERING PHARMACEUTICAL COMPOUNDS
MX2009004965A (es) Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides.
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2007084424A3 (en) Treatment of substance abuse
EP1758458A4 (en) COMPOSITIONS CONTAINING OPIOIDANT AGONISTS
MX2009012523A (es) Composiciones utiles para reducir la nefrotoxicidad y metodos para utilizarlas.
WO2007050802A3 (en) Novel opioid antagonists
WO2012052169A3 (de) Partikelförmige pharmazeutische zusammensetzung mit einem opioid und einem opioid-antagonisten
ZA200806361B (en) Methods and compositions for treating feline hyperthyroidism